UniDoc Announces Purchase Agreement for AGNES Connect Software from AMD Telemedicine

Strategic Acquisition to Enhance UniDoc’s eHealth Software Capabilities

VANCOUVER, BC / March 19, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) (“UniDoc” or the “Company”), an innovator in the eHealth sector, is pleased to announce it has entered into a definitive purchase agreement (the “Agreement”) for the acquisition of the AGNES Connect software from AMD Telemedicine (“AMD”). This software forms the foundation of UniDoc’s previously announced NEIL Connect software platform.

Highlights of proposed acquisition of AGNES Connect:

  • Accelerates the expansion and enhancement of UniDoc’s NEIL Connect software platform.
  • UniDoc gains immediate access to existing AGNES Connect customers and plans continued support and expansion of this client base.
  • Strengthens UniDoc’s integrated AI-driven telehealth offering with secure data-sharing and EMR integration capabilities.

AGNES Connect, is a secure, encrypted, cloud-based clinical examination platform recognized for its robust telemedicine capabilities. The software enables healthcare providers to capture and securely exchange medical data, documents, and images in real-time alongside high-quality video conferencing. AGNES Connect seamlessly integrates into healthcare facilities’ electronic health record (EHR) systems, simplifying clinical workflows and documentation.

Pursuant to the terms of the Agreement, effective March 18, 2025, UniDoc has agreed with AMD to acquire the name “AMD Telemedicine” and related goodwill, together with the AGNES Connect software and related intellectual property, trademarks, customer subscriptions and accounts. As consideration, the Company has agreed to pay AMD US$175,000 in cash plus a revenue share. The acquisition remains subject to customary conditions for transactions of this nature including the approval of the Canadian Securities Exchange, if required. The Company expects closing of the acquisition to occur shortly.

UniDoc CEO Antonio Baldassarre notes, “The proposed acquisition of AGNES Connect will strengthen our NEIL Connect platform, and position UniDoc to deliver a more comprehensive and seamless eHealth solution. This integration will immediately enhance our software capabilities and provide direct access to an established customer network, presenting new opportunities to generate sustainable revenue and enhance shareholder value.”

UniDoc, upon closing of the acquisition, intends to continue to support and expand the existing AGNES Connect customer base, delivering improved software updates and enhanced customer service. The NEIL Connect platform is currently integrated with partners Carefluence and DocBox software, and leverages advanced artificial intelligence (AI) to facilitate more accurate intake/triage (MediOrbis) and more efficient patient monitoring (DocBox), further supporting UniDoc’s mission to bridge gaps in healthcare accessibility and quality.

Ensuring strict adherence to healthcare data protection standards, UniDoc’s NEIL Connect platform that supports compliance with the Health Insurance Portability and Accountability Act (HIPAA). Patient information is securely managed, encrypted, and integrated with hospital and clinical databases, aligning with industry-leading security practices and standards.

UniDoc is committed to further enhancing its telehealth solutions through continuous innovation and strategic growth initiatives, and anticipates leveraging AGNES Connect software once acquired to increase operational efficiencies and drive greater shareholder value.

On Behalf of the Board of Directors,

~Antonio Baldassarre~

Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp.

About UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF)

UniDoc is developing an eHealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician’s office. eHealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company’s belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress.

For further information, please contact:

UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com

Matt Chatterton, Director
Tel: +1 778.613.2082
Email: matt@unidoctor.com
Media Inquiries media@unidoctor.com

Forward-Looking Statements

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “will be”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the highlights of the proposed acquisition of AGNES Connect, the expansion and enhancement of UniDoc’s NEIL Connect software platform; closing of the acquisition and the timing thereof; the acquisition of the AGNES Connect software and its impact on the business of the Company; the Company continuing to support and expand the existing AGNES Connect customer base, and delivering improved software updates and enhanced customer service; the acquisition of the AGNES Connect customer base and accounts, the possible expansion of customer accounts; the Company enhancing shareholder value, generating sustainable growth, increasing operational efficiencies and bridging gaps in healthcare accessibility and quality; and the benefits the NEIL Connect software will add to the Company’s products and that it will allow doctors to improve the accuracy of their diagnoses.

Forward-looking information is based on the assumptions, estimates, analysis, and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; the Company’s ability to secure additional financing on reasonable terms; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all; as well as all of the other risks as described in the Company’s annual management discussion and analysis dated July 31, 2024 under the heading “Risks Factors.” Accordingly, readers should not place undue reliance on any such forward-looking information.

Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Sign Up For News Alerts

Enter your details below and we will add you to our News Alerts list.

Austin Thornberry

Director

Mr. Thornberry is a seasoned finance professional with a background in advising new companies in the venture capital market. He brings extensive experience working with high-growth companies across numerous industries through his past work in the technology and innovation banking group at the Bank of Montreal and in the financial services arm of Ernst & Young advising on multiple capital markets transactions. Mr. Thornberry has split his time working in Toronto, Ont., and Vancouver, B.C. He obtained his bachelor of commerce at McGill University and has held the CPA, CA, designation since 2019.

Matt Chatterton

DIRECTOR

Mr. Chatterton brings over 18 years of experience in development and execution of complex projects. His  expertise includes project management, facility management, logistics, and supply side processes and  procedures at a number of operations in Canada and internationally. He has  been involved in the public markets for the last three years managing IPO processes and transitioning  businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of  Canada’s Queens University with a Bachelor’s degree in Engineering Chemistry (2001) and Master’s degree in Chemical Process Engineering (2003).

Sina Pirooz

Director

Mr. Pirooz is a registered and practicing pharmacist, and has been a professional member of the College of Pharmacists of British Columbia since 2003, with over 20 years of pharmaceuticals and pharmacy management experience. As owner of a compounding pharmacy, Mr. Pirooz has been dispensing pharmaceuticals for over 18 years and provides pharmacist and pharmacy management services to many of Canada’s largest pharmacy chains and drug stores. Mr. Pirooz is also the CEO and a director of Genix Pharmaceuticals Corporation, a company listed for trading on the TSXV.

Dr. Sazzad Hossain, PhD

Chief Scientific Officer

He is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company. Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada. Working with the Canadian government he helped establish the pharmacology laboratory to evaluate safety and efficacy of cannabinoid-based and other drugs under development for cancer, cardiovascular and ocular diseases.

Jacob Moshinsky

Chief Operating Officer

Jacob is the CEO & founder of MoviWear a GPS, fall down detection & remote vital-sign monitoring platform, alerting caregivers of real-time emergencies. Jacob is a communications and technology expert with over 15 years’ experience in the field. the NurtureWatch health monitoring Smartwatch and MoviWearMED remote vital sign monitoring platform Prior to MoviWear, Jacob worked in both the Canadian telecom and the CPG industry. He led the Product Development and Business Strategy team at TELUS for the Small Business Portfolio. Jacob also worked in various product and service management roles within Rogers Communications where he launched and managed wireless and wireline products.

Antonio Baldassarre

CEO, President and Director

Mr. Baldassarre has held senior management and director positions of new business start-ups and established multinational organizations with over 30 years of experience in the Security, Information Technology and Communications industries. With leadership skills in management of international operations, shareholder exit strategies, and overall business development, he has utilized a wide range of strategic programs to maximize organic growth into specific industry segments through OEM, alliances, and direct multi-level distribution channels.

Mr. Baldassarre is able to plan, organize and direct all aspects of a Corporation from Operations, P&L oversight, product distribution, Product promotions, sales and development activities and initiatives utilizing my extensive marketing/sales senior management experience with developed abilities in team leadership and program/campaign development. Directly involved in the growth, branding and ultimately optimizing market share, product awareness, revenues, profitability and shareholder value.

Mr. Baldassare is also the President of LRG Security Canada Inc. and LRG Security Europe.

Franco Staino

DIRECTOR

Mr. Franco Staino is a business professional with over 40 years experience in the pharmaceutical industry. Mr. Staino has significant experience in drug safety, traceability and anti-counterfeiting measures and has designed and implemented programs for the Italy National Health Service, the Ministry of Health and the Polygraphic Institute and State Mint.

Mr. Staino currently holds multiple positions including being the control representative of Carlucci a leading company engaged in the production of self-adhesive labels for consumer goods with high specialization for the pharmaceutical sector, and President of the Board of Directors of Topharmacia, a company that deals with the integral management of pharmacies throughout Italy in order to improve their ability to provide social and commercial services, to connect industrial marketing policy to that of the pharmacy, to offer tools in able to guarantee the financial balance of the companies involved.